Eric Reish, MD
Ophthalmology · Alexandria, LANPI 1801086202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,523 of the $23,190 with a category attached, or 84.2%. 30 manufacturers reported payments, led by Alcon at 34.8% of the total. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 410 payments — averaging $56.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$8K
- Glaukos Corporation$6K
- Sight Sciences, Inc.$2K
- Ivantis, Inc$2K
- NEW World Medical,inc.$1K
- AbbVie$858
- plus $4K from 24 others
Across 68 payments — averaging $1976.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$117K
- Ivantis, Inc$11K
- Alcon Research LLC$4K
- Rxsight Inc$2K
What the payments were for
- Consulting fees$2,92513%
- Travel & lodging$4202%
- Food & beverage$19,52384%
- Education$2001%
- Gifts$1000%
- Entertainment$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 145 | $8,080 |
| Glaukos Corporation | 46 | $5,683 |
| Sight Sciences, Inc. | 33 | $1,875 |
| Ivantis, Inc | 22 | $1,758 |
| NEW World Medical,inc. | 22 | $1,068 |
| AbbVie(2 entities) | 23 | $858 |
| Rxsight Inc | 18 | $717 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $599 |
| Mallinckrodt Hospital Products Inc. | 11 | $391 |
| Biotissue Holdings Inc. | 6 | $353 |
| Aerie Pharmaceuticals, Inc. | 6 | $301 |
| Ocular Therapeutix, Inc. | 16 | $257 |
| Genentech USA, Inc. | 3 | $228 |
| Tarsus Pharmaceuticals, Inc. | 5 | $194 |
| Sun Pharmaceutical Industries Inc. | 6 | $134 |
| Rayner Intraocular Lenses Limited | 5 | $91 |
| Oyster Point Pharma, Inc. | 4 | $82 |
| Dompe US, Inc. | 4 | $81 |
| Merz Pharmaceuticals, LLC | 3 | $71 |
| Amgen(2 entities) | 4 | $70 |
| Apellis Pharmaceuticals, Inc. | 3 | $66 |
| Boston Scientific | 1 | $58 |
| Bausch & Lomb Americas Inc. | 3 | $52 |
| Biogen | 2 | $36 |
| Nova Eye, Inc. | 1 | $22 |
| Tearlab Corp | 1 | $18 |
| Harrow Eye, LLC | 1 | $15 |
| Novartis | 1 | $12 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Omeros Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent infinite Trabecular Micro-Bypass System Model iS3$1,950
- Hydrus Microstent$1,182
- LenSx$777
- TearCare SmartLid$620
- TEARCARE(TM) (2.2) SYSTEM KIT$620
- Photrexa$558
- Clareon$550
- Hydrus$494
- ARGOS$481
- OMNI(R) SURGICAL SYSTEM (US)$422
- iStent inject W$383
- iStent Trabecular Micro-Bypass System Model iS3$311
- SION SURGICAL INSTRUMENT$282
- iStent inject Trabecular Micro-Bypass Stent System$279
- KXL System$243
- Tecnis IOL$241
- Rhopressa$236
- Rocklatan$236
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$229
- Prokera$171
How this compares
$23,190 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 179 | $151,337 |
| Prednisolone Acetate | 923 | $43,613 |
| RhopressaNetarsudil Mesylate | 112 | $43,501 |
| CombiganBrimonidine Tartrate/Timolol | 111 | $31,689 |
| XiidraLifitegrast | 40 | $29,599 |
| Cyclosporine | 64 | $22,578 |
| MoxifloxacinMoxifloxacin Hcl | 917 | $21,249 |
| Ketorolac Tromethamine | 888 | $17,199 |
| LumiganBimatoprost | 43 | $13,121 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 89 | $12,792 |
| Latanoprost | 1,188 | $11,579 |
| TyrvayaVarenicline Tartrate | 16 | $10,175 |
| Travoprost | 54 | $8,258 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $7,734 |
| Alphagan PBrimonidine Tartrate | 18 | $6,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $858 | $202,670351 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $301 | $51,234132 claims |
| Bausch & Lomb Americas Inc.Xiidra | $52 | $29,59940 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $82 | $10,17516 claims |
| AlconSimbrinza | $8,080 | $4,50120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Alexandria
- Michael RedmondAlexandria$24K
- Patrick RedmondAlexandria$11K
- Thomas NortonAlexandria$8K
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.